Evidence map›Paper›PMID 39896287›Full record

ArticleMaterials today. Bio2025

A bioprinted animal patient-derived breast cancer model for anti-cancer drug screening.

Xuan Mei, Maria Fernanda Uribe Estrada, Muhammad Rizwan, Izeia Lukin, Begoña Sanchez Gonzalez, Jose Gerardo Marin Canchola, Valeria Velarde Jarquín, Ximena Salazar Parraguez, Francisco Del Valle Rodríguez, Carlos Ezio Garciamendez-Mijares and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. 3D bioprinting innovations: a new frontier in breast cancer research.Medical oncology (Northwood, London, England) · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Xuan MeiDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Maria Fernanda Uribe EstradaDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Muhammad RizwanDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Izeia LukinDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Begoña Sanchez GonzalezDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Jose Gerardo Marin CancholaDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Valeria Velarde JarquínDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Ximena Salazar ParraguezDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Francisco Del Valle RodríguezDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Carlos Ezio Garciamendez-MijaresDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Zeng LinDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Jie GuoDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Zhenwu WangDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Sushila MaharjanDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.
Gorka OriveNanoBioCel Research Group, School of Pharmacy, University of the Basque Country (UPV/EHU), Vitoria-Gasteiz 01006, Spain.
Yu Shrike ZhangDivision of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge 02139, MA, USA.

Funding

High-throughput Imaging-integrated Vascular Model for Understanding Thromboembolism and Therapeutics ScreeningR01HL166522 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Junjie Yao, Y. Shrike Zhang · 2023 to 2026
$2.7M
Biomaterials for embolization and ablation of arterio-venous malformationsR01HL165176 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI, ZHANG, Y. SHRIKE · 2022 to 2025
$2.6M
High-Throughput Volumetric Photoacoustic Imaging of Living Vascularized OrganoidsR01EB028143 · NIBIB · DUKE UNIVERSITY · PI YAO, JUNJIE · 2019 to 2022
$2.0M
A Bioprinted Volumetric Model of Vascularized GlioblastomaR01CA282451 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Kaisorn Lee Chaichana, Y. Shrike Zhang · 2023 to 2026
$1.7M
Recapitulating Ductal Carcinoma on a Chip for Personalized Breast Cancer TherapyR00CA201603 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, Y. SHRIKE · 2019 to 2021
$747k
Multiscale Stereolithogrphic Bioprinting of Stage-Matching Vascularized Tumor ModelsR21EB025270 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, Y. SHRIKE · 2018 to 2020
$726k
NCI NIH HHS R00 CA201603NCI NIH HHS R01 CA282451NHLBI NIH HHS R01 HL165176NHLBI NIH HHS R01 HL166522NIBIB NIH HHS R01 EB028143NIBIB NIH HHS R21 EB025270
6 · The paper itself

Abstract

Animal models are commonly used for drug screening before clinical trials. However, developing these models is time-consuming, and the results obtained from these models may differ from clinical outcomes due to the differences between animals and humans. To this end, 3D bioprinting offers several advantages for drug screening, such as high reproducibility and improved throughput, in addition to the human cells that can be used to generate these models. Here, we report the development of an animal patient-derived

Identifiers

PMID39896287
PMCPMC11782996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.